4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-22-040343
Chief Executive Officer sold 25,000 shares at an average $61.59 ($1,539,862)
- Chief Executive Officer acquired 25,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2022-06-29 | Option exercise | +25,000 | $12.57 | $314,250 | 315,279 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-06-29 | Sale | −20,260 | $61.42 | $1,244,454 | 295,019 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-06-29 | Sale | −4,740 | $62.32 | $295,407 | 290,279 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2022-06-29 | Option exercise · Stock Option (Right to Buy) | −25,000 | 8,333 | D | ||
| Open-market sales · 25,000 sh · avg $61.59 · $1,539,862 | |||||||
Loading xslF345X03/doc4.xml…